SBC Medical Heads to Two New York Investor Conferences in October
October 05, 2026 - by Editor Prism MarketView
After a September schedule that spanned New York, Toronto and Hong Kong, SBC Medical will meet institutional investors at the Maxim Growth Summit on October 14 and The ThinkEquity Conference on October 15.
SBC Medical Group Holdings Incorporated (NASDAQ: SBC), a Medical Services Organization providing management support across a wide range of healthcare fields, announced on September 25, 2026 that it would take part in three investor conferences in October. At each event, the company will give a presentation and hold one-on-one meetings with institutional investors.
The schedule opened with the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 1 and 2. SBC will then appear in person at the Maxim Growth Summit 2026 in New York on October 14, followed by The ThinkEquity Conference 2026, also in New York, on October 15.
A Busy Fall on the Conference Circuit
The October dates extend an active stretch of investor outreach. SBC lined up five conferences in September, including the H.C. Wainwright 28th Annual Global Investment Conference in New York, the CLSA 33rd Investors’ Forum in Hong Kong, and virtual events hosted by Sidoti and Lytham Partners. The September schedule also included the ArcStone-Kingswood Growth Summit in Toronto on September 16, where Head of IR Hikaru Fukui presented the company’s recent milestones and growth strategy.
The outreach reflects a stated priority. In August, Chairman and CEO Yoshiyuki Aikawa said SBC is pursuing “sustained EPS growth and achieving fair equity valuation for our shares in the capital markets as two wheels of the same cart.”
What Investors Will Hear About
The meetings come after a quarter in which profit growth far outpaced revenue. For the three months ended June 30, 2026, total revenue rose 13% year over year to $49 million. Net income attributable to SBC climbed 335% to $11 million, and Adjusted EBITDA, a non-GAAP measure, grew 32% to $20 million. Basic EPS reached $0.10, up from $0.02 a year earlier.
The network of clinics SBC supports also kept growing. At the end of June it counted 287 locations, 34 more than a year earlier, and patient visits over the last twelve months reached 6.9 million, up 10%. SBC expects fee revisions for its call center services, together with expanded support for Rize Clinic and Gorilla Clinic, to add approximately $15 million in annual service fees if the impact is realized for a full year.
SBC has continued to add locations under its multi-brand strategy since the quarter closed. NEO Skin Clinic, an aesthetic dermatology brand, opened in Nagoya on August 22, followed by Kobe on August 29. The Kobe clinic is the brand’s fourth location and its first in the Kansai region.
Balance Sheet and Growth Priorities
SBC ended June with $184 million in cash and cash equivalents, up from $164 million at December 31, 2025. Operating activities provided $32 million in net cash in the first half of 2026, compared with $6 million used in the same period of 2025.
Management plans to deepen its multi-brand strategy in aesthetic dermatology in Japan while building non-aesthetic healthcare into a “second growth engine.” Internationally, SBC plans to grow through its collaboration with OrangeTwist in the United States and an ASEAN expansion anchored in Thailand. The company is also preparing to enter the longevity market.
Share this article:
Disclaimer
This communication was produced by Prism MarketView. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PRISM” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PRISM see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…
This communication was produced by Prism MarketView, “PRISM”. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PRISM, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.
“PRISM” and its affiliates are not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does “PRISM” engage in any activities that would require such registrations. “PRISM” and its affiliates do not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication.
Our articles, reports/releases and videos are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We only publish favorable information because we are compensated to publish only favorable information. We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest.
This communication may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to, market conditions, regulatory developments, and other factors beyond the control of the profiled company. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. PRISM undertakes no obligation to update or revise any such statements.
The contributors may buy and sell securities before, during and after any particular article, report and publication. In no event shall “PRISM” or affiliates be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by “PRISM”, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages.Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. Never invest in any stock featured by “PRISM” and its affiliates unless you can afford to lose your entire investment.We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the Financial Industry Regulatory Authority (FINRA) at www.finra.org.
